A portion of the CRADA research program is being sponsored by Intensity Therapeutics.
CRADA will explore the processes by which the company’s products activate immune responses against cancer and possible synergy of its products with a new class of NKT cell agonists developed by the NCI.
According to NCI chief of the Vaccine Branch and head of the Molecular Immunogenetics and Vaccine Research Section Jay Berzofsky Intensity’s in vivo tumor regression and immune activation data generated to date are impressive.
Intensity Therapeutics president and CEO Lewis Bender said the company is happy to partner with the world’s leading cancer research organization, the National Cancer Institute.
"Dr. Jay Berzofsky is one of the foremost scientists in the field of cancer immunology," Bender said.
"It is an honor for Intensity Therapeutics to be collaborating with him and his department’s distinguished group of scientists, including Dr. Masaki Terabe, the Deputy Section Head, who is leading the research on NCI’s immune-enhancer."
CRADA is one of the principal mechanisms used by federal labs to engage in collaborative efforts with non-federal partners to achieve goals of technology transfer and it is intended to be a flexible mechanism that can be adapted to a variety of types of collaborative efforts between federal and non-federal organizations.